- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Impact BioMedical Inc. Announces Issuance of Canadian Patent for Linebacker Technology Targeting Inflammatory Disease | 35 | GlobeNewswire (Europe) | HOUSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE: IBO), is thrilled to announce a significant milestone in its innovative Linebacker technology platform. The Canadian Intellectual... ► Artikel lesen | |
| 08.10. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.10. | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates | 3 | GlobeNewswire (USA) | ||
| 26.09. | Impact BioMedical erhält neues US-Patent für Insektenschutzmittel | - | Investing.com Deutsch | ||
| 26.09. | Impact BioMedical secures new US patent for insect repellent | 1 | Investing.com | ||
| 26.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. (NYSE: IBO) Announces 3F US Patent Issue | 68 | GlobeNewswire (Europe) | HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. ("IBO") is pleased to announce that the US Patent and Trademark Office has issued U.S. Patent No. 11,985,973 entitled "Insect Repelling... ► Artikel lesen | |
| 20.09. | DSS Inc. buys $2,330 worth of Impact Biomedical shares | 1 | Investing.com | ||
| 19.09. | DSS Inc. buys Impact Biomedical shares worth over $150k | 2 | Investing.com | ||
| 17.09. | IMPACT BIOMEDICAL INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces the Closing of its Initial Public Offering | 138 | GlobeNewswire (Europe) | NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness, today announced the... ► Artikel lesen | |
| 17.09. | Consumer wellness product developer Impact BioMedical prices IPO at $3 low end | 1 | Renaissance Capital | ||
| 16.09. | DSS, Inc. Celebrates Impact BioMedical Inc.'s Successful IPO and Proudly Advances Shareholder Value | 75 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a dedicated supporter and investor in Impact BioMedical Inc. (NYSE American: IBO), is delighted to announce the successful... ► Artikel lesen | |
| 16.09. | Impact BioMedical Prices 1.5 Mln IPO At $3 Per Share | 427 | AFX News | WASHINGTON (dpa-AFX) - Impact BioMedical Inc. (IBO), Monday announced the pricing of its initial public offering of 1.5 million shares at $3.00 per share. The offering is expected to close on... ► Artikel lesen | |
| 16.09. | Impact BioMedical, Inc.: Impact BioMedical Inc. Announces Pricing of Initial Public Offering | 134 | GlobeNewswire (Europe) | NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a company discovering and developing new offerings in human healthcare and wellness today announced the pricing... ► Artikel lesen | |
| 27.08. | IMPACT BIOMEDICAL INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 23.08. | IMPACT BIOMEDICAL INC. - 8-A12B/A, Registration of securities | 1 | SEC Filings | ||
| 20.08. | IMPACT BIOMEDICAL INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 13.08. | IMPACT BIOMEDICAL INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 09.08. | IMPACT BIOMEDICAL INC. - S-1/A, General form for registration of securities | 1 | SEC Filings | ||
| 08.08. | IMPACT BIOMEDICAL INC. - 8-A12B, Registration of securities | - | SEC Filings |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LONGBOARD PHARMACEUTICALS | 59,05 | 0,00 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 32,990 | 0,00 % | Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 4.5% After Analyst Upgrade | ||
| NEUMORA THERAPEUTICS | 16,080 | 0,00 % | Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down Following Insider Selling | ||
| ADMA BIOLOGICS | 16,570 | 0,00 % | Adma Biologics Aktie: Erholung nach starkem Kursrückgang | ||
| EVOTEC | 5,370 | +1,99 % | Aixtron, BYD, Deutz, Evotec, Nordex, Vonovia - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,180 | 0,00 % | Rani Therapeutics Holdings, Inc. - 8-K, Current Report | ||
| DISC MEDICINE | 47,640 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week | WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,850 | 0,00 % | Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics | ||
| QIAGEN | 40,445 | -1,00 % | QIAGEN N.V.: QIAGEN erweitert Automationsportfolio für Flüssigbiopsien zur Anwendung in Onkologie, Pränatalmedizin und Organtransplantation | Portfolioerweiterung stärkt QIAGENs Marktführerschaft bei automatisierten Lösungen für nicht-invasive Flüssigbiopsie in Kombination mit kompletten Workflows // Aktualisiertes ccfDNA-Kit mit urinbasiertem... ► Artikel lesen | |
| TANGO THERAPEUTICS | 6,910 | 0,00 % | Leerink maintains Outperform rating on Tango Therapeutics stock | ||
| PRAXIS PRECISION MEDICINES | 72,11 | 0,00 % | Praxis Precision Medicines überarbeitet Abfindungsregelungen für Führungskräfte | ||
| JANUX THERAPEUTICS | 52,71 | 0,00 % | Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,770 | 0,00 % | Avidity Biosciences' drug cleared by FDA | ||
| ARCELLX | 89,91 | 0,00 % | Arcellx stock soars to all-time high of $88.67 amid robust growth | ||
| RECURSION PHARMACEUTICALS | 6,675 | 0,00 % | Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip? |
IMPACT BIOMEDICAL INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMPACT BIOMEDICAL INC finden Sie auf Wallstreet Online.
